Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate
M Manns, P Buggisch, S Mauss, T Berg, G Teuber, M Schuchmann, P Marcellin, J Heathcote, J Sorbel, F Rousseau · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: Tenofovir disoproxil fumarate (TDF) is active against lamivudine resistant hepatitis B virus (HBV). Response to TDF treatment in a subset of patients from the phase 3, studies 102 (HBeAg-negative patients) and 103 (HBeAg-positive patients) previously treated for >12 weeks with lamivudine or emtricitabine (LAM-experienced) was compared to LAM-naïve patients in these two studies. Goal: To determine if the safety and efficacy of TDF treatment is comparable at week (W) 96 in LAM-experienced and LAM-naïve patients. Methods: In studies 102 and 103, CHB patients were randomized 2:1 to double-blind, once d…
